EMAIL THIS PAGE TO A FRIEND

Brain structure & function

Anatomical and electrophysiological changes in striatal TH interneurons after loss of the nigrostriatal dopaminergic pathway.


PMID 24173616

Abstract

Using transgenic mice that express enhanced green fluorescent protein (EGFP) under the control of the tyrosine hydroxylase (TH) promoter, we have previously shown that there are approximately 3,000 striatal EGFP-TH interneurons per hemisphere in mice. Here, we report that striatal TH-EGFP interneurons exhibit a small, transient but significant increase in number after unilateral destruction of the nigrostriatal dopaminergic pathway. The increase in cell number is accompanied by electrophysiological and morphological changes. The intrinsic electrophysiological properties of EGFP-TH interneurons ipsilateral to 6-OHDA lesion were similar to those originally reported in intact mice except for a significant reduction in the duration of a characteristic depolarization induced plateau potential. There was a significant change in the distribution of the four previously described electrophysiologically distinct subtypes of striatal TH interneurons. There was a concomitant increase in the frequency of both spontaneous excitatory and inhibitory post-synaptic currents, while their amplitudes did not change. Nigrostriatal lesions did not affect somatic size or dendritic length or branching, but resulted in an increase in the density of proximal dendritic spines and spine-like appendages in EGFP-TH interneurons. The changes indicate that electrophysiology properties and morphology of striatal EGFP-TH interneurons depend on endogenous levels of dopamine arising from the nigrostriatal pathway. Furthermore, these changes may serve to help compensate for the changes in activity of spiny projection neurons that occur following loss of the nigrostriatal innervation in experimental or in early idiopathic Parkinson's disease by increasing feedforward GABAergic inhibition exerted by these interneurons.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

14340
(+)-Bicuculline, ≥97.0% (TLC)
C20H17NO6
H4381
6-Hydroxydopamine hydrochloride, ≥97% (titration), powder
C8H11NO3 · HCl
455830
Ammonium hydrogen difluoride, 99.999% trace metals basis
H5F2N
224820
Ammonium hydrogen difluoride, reagent grade, 95%
H5F2N
01110
Ammonium hydrogen difluoride, puriss., ≥97.5%
H5F2N
C7527
Choline chloride, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥98%
C5H14ClNO
C7017
Choline chloride, ≥99%
C5H14ClNO
1133547
Choline chloride, United States Pharmacopeia (USP) Reference Standard
C5H14ClNO
C1879
Choline chloride, ≥98%
C5H14ClNO
26978
Choline chloride, BioUltra, ≥99.0% (AT)
C5H14ClNO
PHR1251
Choline chloride, Pharmaceutical Secondary Standard; Certified Reference Material
C5H14ClNO
A5282
DL-2-Amino-5-phosphonopentanoic acid, solid
C5H12NO5P
A6553
DL-2-Amino-5-phosphonovaleric acid lithium salt, ~95%
C5H11LiNO5P
M2392
Meprobamate, analytical standard
C9H18N2O4
M0400000
Meprobamate, European Pharmacopoeia (EP) Reference Standard
C9H18N2O4
M-039
Meprobamate solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C9H18N2O4
A4929
N,N′-Bis(acryloyl)cystamine, BioReagent, suitable for electrophoresis
C10H16N2O2S2
14460
N,N′-Bis(acryloyl)cystamine, BioXtra, ≥97.0% (HPLC)
C10H16N2O2S2
63183
N-(3-Maleimidopropionyl)biocytin, ≥75% (HPLC)
C23H33N5O7S